Kathryn Peterson, APRN
Adult Health · Hamden, CTNPI 1750969705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 513 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,540 and has fallen 97.4% since, to $91 in 2025. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 513 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Boehringer Ingelheim$1K
- Novo Nordisk$977
- AstraZeneca$703
- Sanofi-aventis U.S. LLC$594
- Amgen$581
- plus $5K from 29 others
What the payments were for
- Food & beverage$10,929100%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 116 | $1,940 |
| Boehringer Ingelheim | 37 | $1,204 |
| Novo Nordisk | 65 | $977 |
| AstraZeneca(2 entities) | 33 | $703 |
| Sanofi-aventis U.S. LLC | 23 | $594 |
| Amgen(2 entities) | 24 | $581 |
| Bayer | 20 | $537 |
| Corcept Therapeutics | 16 | $497 |
| Abbott | 25 | $488 |
| Xeris Pharmaceuticals, Inc. | 24 | $456 |
| Radius Health, Inc. | 15 | $423 |
| AbbVie | 20 | $306 |
| Dexcom, Inc. | 10 | $287 |
| Cequr Corporation | 3 | $244 |
| Insulet Corporation | 11 | $231 |
| Mannkind Corporation | 9 | $205 |
| Currax Pharmaceuticals LLC | 11 | $188 |
| IBSA Pharma Inc. | 8 | $175 |
| Amneal Pharmaceuticals LLC | 6 | $140 |
| Kyowa Kirin, Inc. | 5 | $104 |
| Medtronic | 4 | $101 |
| Amarin Pharma, Inc. | 5 | $89 |
| Tandem Diabetes Care, Inc. | 3 | $72 |
| Ultragenyx Pharmaceutical Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Antares Pharma, Inc. | 2 | $48 |
| Halozyme Inc | 2 | $48 |
| Lifescan, Inc. | 2 | $40 |
| Amryt Pharma Holdings Ltd | 2 | $39 |
| Zealand Pharma US, Inc. | 2 | $34 |
| BD | 1 | $24 |
| Clarus Therapeutics Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$499
- Kerendia$125
- EVENITY$125
- RYBELSUS$125
- DEXCOM G6 TRANSMITTER$122
- CeQur Simplicity$101
How this compares
$10,972 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 307 | $605,815 |
| OzempicSemaglutide | 161 | $326,120 |
| JardianceEmpagliflozin | 193 | $265,062 |
| TrulicityDulaglutide | 97 | $177,413 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $64,741 |
| FarxigaDapagliflozin Propanediol | 47 | $57,221 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $56,008 |
| TradjentaLinagliptin | 39 | $54,257 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $44,244 |
| RybelsusSemaglutide | 19 | $42,744 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $27,969 |
| JanuviaSitagliptin Phosphate | 32 | $27,035 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 119 | $24,959 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $12,786 |
| HumalogInsulin Lispro | 20 | $9,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,940 | $792,574424 claims |
| Novo NordiskOzempic, Rybelsus | $977 | $368,864180 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $1,204 | $347,288251 claims |
| AstraZenecaFarxiga | $703 | $57,22147 claims |
| MerckJanuvia | $18 | $27,03532 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $140 | $2,531119 claims |
| AbbVieSynthroid | $306 | $1,11113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in Hamden
- Gustavo Herrera-BritoHamden$4K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Gretchen MichaelsonSouth Windsor$169K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.